Explore the KeratOPrinter project, an innovative solution to corneal shortages using advanced bioprinting technology.

Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease ...

The study evaluated 14 patients that were treated with cultivated autologous limbal epithelial cells (CALEC) and followed ...

Aurion will operate as a separate company with full support from Alcon to advance its clinical-stage allogeneic cell therapy asset, AURN001, into Phase 3 for corneal edema secondary to corneal ...

The study was led by Harvard Medical School and Massachusetts Eye and Ear researchers and surgeons. The researchers reported ...

Aurion is developing AURN001, a clinical-stage allogeneic cell therapy asset, for corneal edema secondary to corneal ...

Raised $10.75 million in private placement financing with participation from SR One, Cormorant Asset Management, Woodline Partners and another life sciences-focused investor -- -- Cash resources of ...